Bionumerik pharmaceuticals acquired

Author: bbvt

August undefined, 2024

WebAcquired Party. BioNumerik Pharmaceuticals, Inc. Granting Status. Granted. Acquired Entities. BioNumerik Pharmaceuticals, Inc. More Resources. HSR Annual Reports; … WebBionumerik Pharmaceuticals designs and develops small molecule drugs for the treatment of cancer and prevention of side effects associated with existing cancer therapies.

BioNumerik Pharmaceuticals Appoints Steve Carchedi to Board of …

WebNov 18, 2024 · 31% of BioNumerik Pharmaceuticals employees are Asian. 18% of BioNumerik Pharmaceuticals employees are Hispanic or Latino. The average … WebFeb 7, 2008 · SAN ANTONIO, Feb. 7 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. today announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an … impact of diabetes on health

BioNumerik Pharmaceuticals Inc. - Company Profiles - BCIQ

WebAug 1, 2006 · BioNumerik has two drug candidates in late-stage clinical development: Tavocept(TM) and Karenitecin (BNP1350). Contacts: Takeda Pharmaceutical Company Limited Corporate Communications Dept. (PR/IR) Seizo Masuda [email protected] Tel: +81-6-6204-2060 BioNumerik Pharmaceuticals, Inc. … WebCompany Description: BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential … WebAug 27, 2009 · BioNumerik Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT00966914 Other Study ID Numbers: DMS32212R : First Posted: August 27, 2009 Key Record Dates: Last Update Posted: July 13, 2024 Last Verified: July 2024 Additional relevant MeSH terms: Layout table for MeSH terms ... list the 3 domains

Lantern Pharma Announces Transaction to Evaluate BioNumerik…

BioNumerik Pharmaceuticals Company Profile: Funding

WebJun 14, 2012 · SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve Carchedi to BioNumerik's Board of Directors. Web51 to 200 Employees. Type: Company - Private. Industry: Biotech & Pharmaceuticals. Revenue: $5 to $25 million (USD) Competitors: Unknown. BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late ... impact of depletion of resourcesWebAug 8, 2016 · DALLAS--(BUSINESS WIRE)--Lantern Pharma, Inc. (Dallas, TX, US) and BioNumerik Pharmaceuticals, Inc. of San Antonio, Texas have entered into an … impact of diabetes on aboriginal community

"WebBioNumerik Pharmaceuticals, Inc. Lantern Pharma, Inc. By: /s/ David R. Margrave : By: /s/ Arunkumar Asaithambi: Name: Name: Arunkumar Asaithambi, Ph.D. Title: Title: Chief … " - Bionumerik pharmaceuticals acquired

Bionumerik pharmaceuticals acquired

BioNumerik Pharmaceuticals - Funding, Financials, Valuation

WebJan 21, 2010 · BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas, is focused on the discovery, development and commercialization of novel drugs for the treatment of cancer and cancer supportive care ...

Did you know?

WebJul 17, 2008 · SAN ANTONIO, July 17 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months). The trial … WebOperating Agreement • August 24th, 2004 • Bionumerik Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware

WebBioNumerik Pharmaceuticals: BioNumerik Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 SummaryBioNumerik … WebBioNumerik Pharmaceuticals General Information Description Operator of an oncology pharmaceutical company focused on discovering and developing novel pharmaceutical …

WebMar 2, 2001 · The following is an excerpt from a S-1 SEC Filing, filed by BIONUMERIK PHARMACEUTICALS INC on 3/2/2001. Next Section: Previous Section ... was received by the receiving party from a third party who did not acquire it, directly or indirectly, from the disclosing party under any obligation of confidentiality and which the third party is free to ... WebBioNumerik Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drugs that help in the treatment …

WebFunding. BioNumerik Pharmaceuticals has raised a total of $63.3M in funding over 3 rounds. Their latest funding was raised on Nov 8, 2012 from a Venture - Series Unknown round. BioNumerik Pharmaceuticals is funded by Takeda. BioNumerik Pharmaceuticals has a post-money valuation in the range of $10M to $50M as of Dec 31, 2012, according …

WebDeveloping and commercializing drugs for treating cancer BioNumerik Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drugs that help in … impact of diabetes on health care systemWebJun 14, 2012 · SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve Carchedi to BioNumerik's Board of Directors.. Mr. Carchedi brings extensive pharmaceutical industry and oncology product commercialization experience to the … impact of dementia diagnosis on patientWebNov 8, 2012 · BioNumerik Pharmaceuticals raised $10,190,500 / Series Unknown. Discover more funding rounds . Funding Round ... impact of diabetes on nhsWebMar 18, 2008 · SAN ANTONIO and TOKYO, March 18 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") and ASKA Pharmaceutical Co., Ltd. ("ASKA") … impact of diabetes on wound healingWebMar 18, 2008 · SAN ANTONIO and TOKYO, March 18 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") and ASKA Pharmaceutical Co., Ltd. ("ASKA") … impact of depression on familyWebJan 21, 2010 · BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas, is focused on the discovery, development and commercialization of novel drugs for the … impact of diabetes on societyWebBioNumerik Pharmaceuticals focuses on the discovery, development, and commercialization of novel drugs for the treatment of cancer and cancer-supportive care. It provides drugs by merging medicine, quantum and statistical mechanics, pharmaceutical development, and supercomputing. The company was founded in 1992 and is based in … list the 2 types of contract